Phase III, open-label, long-term safety study of topical RT 001 [botulinum toxin A] for the treatment of lateral canthal lines
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 May 2015
Price : $35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Facial wrinkles
- Focus Adverse reactions; Registrational
- 13 May 2015 According to a Revance Therapeutics media release, status changed from recruiting to active, no longer recruiting.
- 26 May 2014 New trial record
- 13 May 2014 Interim data is expected in 2015, according to a Revance Therapeutics media release.